A REVIEW OF LINK ALTERNATIF MBL77

For individuals with symptomatic disease requiring therapy, ibrutinib is often recommended based upon 4 phase III randomized clinical trials comparing ibrutinib with chlorambucil monotherapy106 along with other usually employed CIT mixtures, namely FCR, bendamustine plus rituximab and chlorambucil as well as obinutuzumab (ClbO).107–109 Ibrutinib